Xeris Biopharma Q2 Revenue +29% to $92.1M; Tightens FY26 Guidance
Xeris Biopharma Holdings, Inc. reported strong second quarter 2026 financial results, with total revenue increasing 29% year-over-year to $92.1 million and net product revenue growing 34% to $91.0 million. This growth was primarily driven by an 81% surge in Recorlev net revenue to approximately $57 million. The company tightened its full-year 2026 total revenue guidance to $385 million to $390 million, reflecting confidence in its business trajectory. Despite a net loss of $31.1 million due to a one-time non-cash charge related to Convertible Notes exchange agreements, Adjusted EBITDA improved to $19.3 million. Key business highlights included a Notice of Allowance for a new Keveyis patent extending protection through at least 2039 and the elimination of all 2028 Convertible Notes.
Key Highlights
- Total revenue increased 29% year-over-year to $92.1 million in Q2 2026.
- Net product revenue grew 34% year-over-year to $91.0 million.
- Recorlev net revenue surged 81% year-over-year to approximately $57 million.
- Tightened full-year 2026 total revenue guidance to $385 million to $390 million.
- Reported a net loss of $31.1 million in Q2 2026, primarily due to a one-time non-cash charge.
- Adjusted EBITDA improved to $19.3 million in Q2 2026, up $6.7 million year-over-year.
- Received a Notice of Allowance for a new Keveyis patent, extending protection through at least 2039.
- Eliminated approximately $23.0 million of 2028 Convertible Notes through exchange agreements.
Price Impact
More from XERS